SIRT1 and Hepatic fibrosis: In the present study, we hypothesized that a SIRT1/2 inhibitor, due to its SIRT1/2 deacetylase inhibition activity, can attenuate HSC activation and HFD-induced hepatic fibrosis in diabetic rats.